AU2008206702A1 - Thiazolidine derivatives and methods for the preparation thereof - Google Patents

Thiazolidine derivatives and methods for the preparation thereof Download PDF

Info

Publication number
AU2008206702A1
AU2008206702A1 AU2008206702A AU2008206702A AU2008206702A1 AU 2008206702 A1 AU2008206702 A1 AU 2008206702A1 AU 2008206702 A AU2008206702 A AU 2008206702A AU 2008206702 A AU2008206702 A AU 2008206702A AU 2008206702 A1 AU2008206702 A1 AU 2008206702A1
Authority
AU
Australia
Prior art keywords
trifluorophenyl
thiazolidine
amino
butanoyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008206702A
Other languages
English (en)
Inventor
Jin Hee Ahn
Hyae Gyeong Cheon
Ni Na Ha
Won Hoon Jung
Nam Sook Kang
Seung Kyu Kang
Ki Young Kim
Sun Young Kim
Sung Gyu Kim
Sung Soo Kim
Jae Hong Kweon
Sang Dal Rhee
Min Ki Shin
Sang Kwon Sohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Chemical Technology KRICT
Yungjin Pharmaceutical Co Ltd
Kainos Medicine Inc
Original Assignee
Korea Research Institute of Chemical Technology KRICT
Yungjin Pharmaceutical Co Ltd
Kainos Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Chemical Technology KRICT, Yungjin Pharmaceutical Co Ltd, Kainos Medicine Inc filed Critical Korea Research Institute of Chemical Technology KRICT
Publication of AU2008206702A1 publication Critical patent/AU2008206702A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2008206702A 2007-01-16 2008-01-16 Thiazolidine derivatives and methods for the preparation thereof Abandoned AU2008206702A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020070004577A KR100848491B1 (ko) 2007-01-16 2007-01-16 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
KR10-2007-0004577 2007-01-16
PCT/IB2008/000773 WO2008087560A2 (en) 2007-01-16 2008-01-16 Thiazolidine derivatives and methods for the preparation thereof

Publications (1)

Publication Number Publication Date
AU2008206702A1 true AU2008206702A1 (en) 2008-07-24

Family

ID=39588017

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008206702A Abandoned AU2008206702A1 (en) 2007-01-16 2008-01-16 Thiazolidine derivatives and methods for the preparation thereof

Country Status (11)

Country Link
US (1) US20100048570A1 (enExample)
EP (1) EP2118081A2 (enExample)
JP (1) JP2011509916A (enExample)
KR (2) KR100848491B1 (enExample)
CN (1) CN101720319A (enExample)
AU (1) AU2008206702A1 (enExample)
BR (1) BRPI0806592A2 (enExample)
CA (1) CA2712109A1 (enExample)
IL (1) IL199892A0 (enExample)
MX (1) MX2009007630A (enExample)
WO (1) WO2008087560A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343304B1 (en) 2005-02-16 2015-06-10 Anacor Pharmaceuticals, Inc. Biocidal boronophthalide compounds
KR20080110984A (ko) 2005-12-30 2008-12-22 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
PT1988779E (pt) 2006-02-16 2015-09-04 Anacor Pharmaceuticals Inc Moléculas pequenas contendo boro como agentes antiinflamatórios
KR20150065941A (ko) 2008-03-06 2015-06-15 아나코르 파마슈티칼스 인코포레이티드 소염제로써 붕소가 함유된 소분자
EP2348863A4 (en) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2010028005A1 (en) * 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN103922971B (zh) 2009-03-30 2016-05-11 东亚St株式会社 用于制备二肽基肽酶-iv抑制剂的中间体的改进方法
EP2415754A4 (en) 2009-03-30 2012-08-22 Dong A Pharm Co Ltd IMPROVED METHOD FOR PREPARING A DIPEPTIDYL-PEPTIDASE IV HEMMER AND AN INTERMEDIATE PRODUCT THEREOF
AP4039A (en) * 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060196A1 (en) * 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AP2012006482A0 (en) 2010-03-19 2012-10-31 Anacor Pharmacueticals Inc Boron-containing small molecules as anti-protozoalagent
ES2710105T3 (es) * 2010-04-07 2019-04-23 Glaxosmithkline Llc Proceso para preparar benzoxaboroles
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
SI3251678T1 (sl) 2010-09-07 2022-01-31 Anacor Pharmaceuticals, Inc. Derivati benzoksaborola za zdravljenje bakterijskih okužb
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20150297573A1 (en) 2012-10-24 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
CN103122009B (zh) * 2013-01-09 2015-11-25 江苏吉贝尔药业股份有限公司 两种用于合成他卡西醇支链的重要中间体化合物
CN103012463B (zh) * 2013-01-17 2016-02-10 南京理工大学 (s)-3-甲基-2-(叔丁基二甲基硅氧基)-1-溴丁烷的合成方法
US20160251380A1 (en) 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof
MA41494B1 (fr) 2015-02-12 2020-10-28 Glaxosmithkline Ip No 2 Ltd Composés benzoxaborole substitués en position 4 et utilisations associées
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
AU2790895A (en) * 1994-06-10 1996-01-05 Universitaire Instelling Antwerpen Purification of serine protease and synthetic inhibitors thereof
JP2003535034A (ja) * 1999-11-12 2003-11-25 ギルフォード ファーマシューティカルズ インコーポレイテッド ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
FR2824825B1 (fr) * 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2450579A1 (en) * 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
AU2002360732A1 (en) * 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
CA2504735C (en) * 2002-11-07 2009-06-23 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004050022A2 (en) * 2002-12-04 2004-06-17 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1799639B1 (en) * 2004-10-12 2013-09-04 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation

Also Published As

Publication number Publication date
JP2011509916A (ja) 2011-03-31
US20100048570A1 (en) 2010-02-25
IL199892A0 (en) 2010-04-15
KR20100094337A (ko) 2010-08-26
EP2118081A2 (en) 2009-11-18
KR100848491B1 (ko) 2008-07-28
CA2712109A1 (en) 2008-07-24
WO2008087560A3 (en) 2008-09-12
WO2008087560A9 (en) 2009-07-30
BRPI0806592A2 (pt) 2014-05-06
MX2009007630A (es) 2010-02-15
CN101720319A (zh) 2010-06-02
WO2008087560A2 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
AU2008206702A1 (en) Thiazolidine derivatives and methods for the preparation thereof
AU2020213376B2 (en) Compounds and methods for the targeted degradation of the androgen receptor
AU2015371294B2 (en) Compounds, compositions, and methods for increasing CFTR activity
EP3157917B1 (en) Compounds, compositions and methods of increasing cftr activity
AU2016297886B2 (en) Compounds, compositions and methods of increasing CFTR activity
US11059809B2 (en) Substituted cyanopyrrolidines with activity as DUB inhibitors
CA3069544A1 (en) Compounds and methods for the targeted degradation of androgen receptor
JP6574756B2 (ja) Ｂａｃｅ１阻害剤
TW201823208A (zh) N－醯基胺基酸化合物及其使用方法
WO2016115090A1 (en) Compounds, compositions and methods for increasing cftr activity
SK282753B6 (sk) Deriváty 4-hydroxyfenylalkánových kyselín, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
JP2013527227A (ja) ヘキサフルオロイソプロピルカルバマート誘導体、この調製およびこの治療的用途
US11981644B2 (en) Bicyclic 1,4-diazepanones and therapeutic uses thereof
JP2009167215A (ja) 新規ジアリールアルケン誘導体及び新規ジアリールアルカン誘導体
JP2009522225A (ja) Ｂａｃｅ阻害剤として有用な大環状化合物
US11274092B2 (en) Potassium channel inhibitors
JP6461162B2 (ja) ５−アリール−１−イミノ−１−オキソ−［１，２，４］チアジアジン
TW202039482A (zh) 嗎啉基、哌嗪基、氧氮雜環庚烷基及二氮雜環庚烷基o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃醣苷酶抑制劑
KR20180050408A (ko) 국부 약물 전달용의 비스테로이드성 글루코코르티코이드 수용체 조절제
KR20060052909A (ko) 벤질아민 유도체
KR20170043581A (ko) 2,2,2-트라이플루오로에틸-티아다이아진
JP2006056830A (ja) ２−アリールアミノベンゾオキサゾール誘導体

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period